Platinum-induced hearing loss after treatment for childhood cancer

As, Jorrit W van; Berg, Henk van den; Dalen, Elvira C. van

doi:10.1002/14651858.cd010181.pub2

Cited by 45 publications

(28 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to loss of hearing sensitivity, damage to cochlear hair cells impacts one's ability to recognise subtle differences in sound frequency; this results in difficulty understanding speech, especially in noise (Summers et al, 2013). Persistent tinnitus is also associated with platinum-induced ototoxicity and it is likely under-reported and under-appreciated in children (van As et al, 2016). Ototoxic high-frequency hearing loss may not be readily apparent to caregivers and medical providers.…”

Section: Mechanisms Of Platinum Ototoxicitymentioning

confidence: 99%

Ototoxicity monitoring in children treated with platinum chemotherapy

Brooks

Knight

2017

International Journal of Audiology

View full text Add to dashboard Cite

Hearing loss has important consequences for the survivors of childhood cancer including communication, learning, cognition and quality of life. Due to the presentation and configuration of ototoxic hearing loss, the test frequencies that are prioritised and the sequence of testing may differ from standard paediatric hearing evaluations. Hearing should be monitored during treatment and after completion of therapy.

show abstract

Section: Mechanisms Of Platinum Ototoxicitymentioning

confidence: 99%

Ototoxicity monitoring in children treated with platinum chemotherapy

Brooks

Knight

2017

International Journal of Audiology

View full text Add to dashboard Cite

show abstract

“…Our findings differ from those already reported in the literature. Cisplatin is the most toxic for the cochlea, acting in a dose‐dependent manner and resulting in permanent functional disability with poor quality of life. The risk factors include younger age, higher cumulate doses of cisplatin (>200–400 mg/m 2 ), co‐treatment with others drugs such as vincristine and pre‐existing hearing loss .…”

Section: Discussionmentioning

confidence: 55%

Drug‐induced hearing loss: a case/non‐case study in the French pharmacovigilance database

Favrelière

Delaunay

Lebreton³

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Non-cases were all reports over the same period. We calculated the reporting odds ratio (ROR) with 95% confidence intervals. Among the 555 reports of hearing loss, significant RORs were found for 68 drugs. The main therapeutic classes implicated were antineoplastic agents (n = 240), systemic anti-infective agents (n = 182), immunosuppressants (n = 42) loop diuretics (n = 26), and salicylate analgesics (n = 26). We found signals of hearing loss with azacitidine, vaccines and nevirapine, immunosuppressants such as leflunomide, and biotherapies such as panitumumab and vandetanib. Prescribers should be informed about the potential associations with all these drugs. The role of the pathology itself and the known ototoxic drugs that can be associated do not allow to conclude definitively. Audiograms for the early detection of hearing loss induced by drugs known to be ototoxic are rarely carried out. Preventive treatments exist and must be considered.

show abstract

“…It is known that platinum compound-induced hearing loss may vary from zero to 90.1% 7 . Furthermore, some studies have described that hearing loss may be triggered during the platinum-based therapy, or even develop after the treatment has finished 5,8,9 . Moreover, in the literature there are studies relating possible factors that contribute to the seriousness of the hearing loss.…”

Section: Introductionmentioning

confidence: 99%

Effects of chemotherapy on the auditory system of children with cancer: a systematic literature review

et al. 2020

View full text Add to dashboard Cite

Purpose: to identify and analyze the effects of chemotherapy on the auditory system of children and/or adolescents with cancer treated with cisplatin and carboplatin, assessed through standardized audiological procedures. Methods: studies in Brazilian Portuguese and in English were searched for, as available in the databases Science Direct, PubMed, LILACS, BIREME, Embase, SciELO, Web of Science and Cochrane. The descriptors were: Hearing Loss, Audiology, Child Cancer, Chemotherapy, and Child. Articles with levels 1 and 2 of scientific evidence, published in the last 20 years (1997 to 2017), were considered, of which the audiological results were analyzed, as well as the prevalence of hearing loss in children with cancer undergoing chemotherapy. Results: 3,625 articles were found, of which only 23 were selected for analysis in the present review. Studies have shown a high incidence of sensorineural hearing loss and decrease or even loss of otoacoustic emissions in children and adolescents with cancer, even after the first dose of chemotherapy drugs, with high frequencies being the most affected. Conclusion: there is evidence that both carboplatin and especially cisplatin from the first doses may impair the hearing of children and adolescents, mainly affecting the cochlear function, thus, the importance of long-term audiological monitoring.

show abstract

Platinum-induced hearing loss after treatment for childhood cancer

Abstract: Platinum-induced hearing loss a er treatment for childhood cancer (Review) van As JW, van den Berg H, van Dalen EC van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss a er treatment for childhood cancer.

Cited by 45 publications

References 150 publications

Ototoxicity monitoring in children treated with platinum chemotherapy

Ototoxicity monitoring in children treated with platinum chemotherapy

Drug‐induced hearing loss: a case/non‐case study in the French pharmacovigilance database

Effects of chemotherapy on the auditory system of children with cancer: a systematic literature review

Contact Info

Product

Resources

About